miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 25, 2026

Oil Drops on Signs of US Diplomatic Push to End War With Iran

View original at finance.yahoo.com
Oil Drops on Signs of US Diplomatic Push to End War With Iran (Bloomberg) -- Oil fell on signals that a US diplomatic push to try to end the war with Iran may be gathering pace, eclipsing news of more troops being sent to the region and the Strait of Hormuz remaining mainly shut…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump appears to be seeking serious negotiations with Iran, while also keeping his options open

    60% confidence

  • There was now a 'newfound possibility of diplomacy' but US military operations would continue unabated

    60% confidence

  • The pullback in oil prices reflects the war-risk premium being cut, but this is unlikely to be seen as an all-clear yet because Iran has publicly denied direct talks while military activity continues

    60% confidence

  • Washington was seeking a one-month ceasefire for talks with Iran

    60% confidence

  • The US sent Iran a 15-point plan to end the conflict

    60% confidence

  • Foreign ships are allowed to pass through Strait of Hormuz as long as they aren't supporting acts of aggression against Iran and follow Iranian regulations

    60% confidence

  • Iran had offered a 'present' as a show of good faith in talks related to energy flows through the strait

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Oil Drops on Signs of US Diplomatic Push to End War With Iran — Source | Via News | es.VIA.NEWS